# Meta-NK consortium: A standardized terminology that provides a basis for subsequent studies of the role of human Natural killer (NK) cells in health and disease.

## Article information

**Title:** A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma 

**Authors:**
Olivier Demaria  1 , Guillaume Habif  1 , Marie Vetizou  1 , Laurent Gauthier  1 , Romain Remark  1 , Laura Chiossone  1 , Constance Vagne  1 , Lucas Rebuffet  2 , Rachel Courtois  1 , Caroline Denis  1 , François Le Floch  1 , Marianna Muller  1 , Mathilde Girard-Madoux  1 , Séverine Augier  1 , Julie Lopez  1 , Barbara Carrette  1 , Aurélie Maguer  1 , Jean-Baptiste Vallier  1 , Gwendoline Grondin  1 , William Baron  1 , Justine Galluso  1 , Nadia Yessaad  1 , Marilyn Giordano  1 , Léa Simon  1 , Fabien Chanuc  1 , Audrey Blanchard Alvarez  1 , Ivan Perrot  1 , Cécile Bonnafous  1 , Agnès Represa  1 , Benjamin Rossi  1 , Ariane Morel  1 , Yannis Morel  1 , Carine Paturel  1 , Eric Vivier  1   2   3   4   5


1    Innate Pharma Research Laboratories, Innate Pharma, Marseille, France.
2   Aix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France.
3   APHM, Hôpital de la Timone, Marseille-Immunopôle Profiling Platform, Marseille, France.
4   Paris-Saclay Cancer Cluster, Le Kremlin-Bicêtre, France.
5   Université Paris-Saclay, Gustave Roussy, INSERM, Prédicteurs moléculaires et nouvelles cibles en oncologie, 94800, Villejuif, France.

DOI: 10.1126/sciimmunol.adp3720


**Summary:**
NK cells offer a promising alternative to T cell therapies in cancer. We evaluated IPH6501, a clinical-stage, tetraspecific NK cell engager (NKCE) armed with a non-alpha IL-2 variant (IL-2v), which targets CD20 and was developed for treating B cell non-Hodgkin lymphoma (B-NHL). CD20-NKCE-IL2v boosts NK cell proliferation and cytotoxicity, showing activity against a range of B-NHL cell lines, including those with low CD20 density. Whereas it presented reduced toxicities compared with those commonly associated with T cell therapies, CD20-NKCE-IL2v showed greater killing efficacy over a T cell engager targeting CD20 in in vitro preclinical models. CD20-NKCE-IL2v also increased the cell surface expression of NK cell-activating receptors, leading to activity against CD20-negative tumor cells. In vivo studies in nonhuman primates and tumor mouse models further validated its efficacy and revealed that CD20-NKCE-IL2v induces peripheral NK cell homing at the tumor site. CD20-NKCE-IL2v emerges as a potential alternative in the treatment landscape of B-NHL. 

## Goal of the github
This github project contains the instructions and material to reproduce the analyses reported in the article (and more).
Source code (scripts and dockerfiles) are available in the github repository. 




